NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1279.30 13.80 (1.09%)

25.42% Gain from 52W Low

469.3K NSE+BSE Volume

NSE 25 Jul, 2025 10:06 AM (IST)

106,768

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Estimates Beat

Dr Reddy's Laboratories' Q1FY26 revenue grows 12.4% YoY, beats Forecaster estimates by 2.3% See details

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

31 Jan 2022

1279.30

1.09%

Dr Reddy's Labs (HOLD): Stable quarter, US price erosion continues; cut to HOLD

Hold: Dr. Reddy's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Growth in Q3 driven by product launches and higher volumes, partly offset by US price erosion

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

29 Jan 2022

1279.30

1.09%

Dr Reddy's Laboratories

Buy: Dr. Reddy's Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Numbers in line; launches in FY23 likely drivers APIs, custom pharmaceutical services, biosimilar and complex formulations. It has 13 formulation facilities, nine API manufacturing facilities, one biologics facility and several R&D centres across the globe Q3FY22 Results: Reported steady set of numbers despite Covid revenue vacuum this quarter, in line with our estimates....

Axis Direct downgraded Dr. Reddy's Laboratories Ltd. to Hold with a price target of 1360.0 on 24 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

01 Jan 2022

1279.30

1.09%

Dr Reddys Labs

Buy: Dr. Reddy's Laboratories Ltd.

Sharekhan

Axis Direct downgraded Dr. Reddy's Laboratories Ltd. to Hold with a price target of 1360.0 on 24 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

01 Jan 2022

1279.30

1.09%

Dr Reddys Labs

Buy: Dr. Reddy's Laboratories Ltd.

Sharekhan

Dr. Reddy's Laboratories Ltd. is trading above its 200 day SMA of 1244.6

Dr. Reddy's Laboratories Ltd.

09 Nov 2021

1279.30

1.09%

DR. REDDY'S LABORATARIES

Buy: Dr. Reddy's Laboratories Ltd.

Target

Geojit BNP Paribas

Company is expected to fare well on the back drop of continued growth in revenue along with innovation of new drugs and medications. Hence, we reiterate our BUY rating on the stock with a revised target price of Rs. 5,437 using a target multiple of 23x FY23E adj. EPS. Topline aided by new Medications Q2FY22 revenue grew 17.8% YoY to Rs. 5,787cr, driven by significant growth in Global Generics segment (+19.0% YoY to Rs. 4,747cr) and robust performance from Proprietary Products segment (Rs. 123cr vs Rs. 10cr in Q2FY21, on the account of...

Dr. Reddy's Laborato.. has an average target of 1310.25 from 8 brokers.

Dr. Reddy's Laboratories Ltd.

08 Nov 2021

1279.30

1.09%

Dr. Reddy

Results Update: Dr. Reddy's Laboratories Ltd.

SMC online

segment rose 1,132.00% to Rs 123.20 crore (accounting for 2.07% of total sales). Sales of (accounting for 17.12% of total sales). Sales of Global Generics segment has gone up 19.03% Others segment has gone up 13.96% to Rs 59.60 crore (accounting for 1.00% of total sales). Inter-segment sales came down from Rs 175.10 crore to Rs 161.80 crore....

Axis Direct downgraded Dr. Reddy's Laboratories Ltd. to Hold with a price target of 1360.0 on 24 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

01 Nov 2021

1279.30

1.09%

Dr Reddy's Laboratories

Hold: Dr. Reddy's Laboratories Ltd.

Target

ICICI Securities Limited

Consequent PAT was at | 965.7 crore (up 25.1% YoY) Sep-20 Dec-20 Mar-21 Jun-21 Sep-21 What should investors do? Dr Reddy's share price has grown by ~1.4x over the...

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

28 Jul 2021

1279.30

1.09%

India drives earnings growth, while North America/PSAI drags it down

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

Dr. Reddy's Labs (DRRD) delivered a miss on earnings in 1QFY22, affected by a) higher price erosion in North America (NAM) sales, b) the deferment of offtake by DRRD's customer in the Pharma Services and Active Ingredients (PSAI) segments, and c) quarterly lumpiness in the Tender business in the Russia segment. DRRD exhibited strong growth in Domestic Formulations...